Procter & Gamble Health (BOM:500126) Cyclically Adjusted Revenue per Share: ₹790.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500126 Procter & Gamble Health Ltd BOM:500126
76 GF Score
Price ₹5,760.50
GF Value ₹5,799.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Procter & Gamble Health Cyclically Adjusted Revenue per Share?

Procter & Gamble Health BOM:500126 +1.59% 76 Cyclically Adjusted Revenue per Share is ₹790.61 as of Jun. 2026. GuruFocus rates BOM:500126 with a GF Score™ of 76/100 and a GF Value™ of ₹5,799.13 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Procter & Gamble Health's adjusted revenue per share for the three months ended in Jun. 2026 was ₹219.102. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹790.61 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Procter & Gamble Health's average Cyclically Adjusted Revenue Growth Rate was 4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Procter & Gamble Health was 4.20% per year. The lowest was 3.40% per year. And the median was 3.80% per year.

As of today (2026-09-01), Procter & Gamble Health's current stock price is ₹5760.50. Procter & Gamble Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹790.61. Procter & Gamble Health's Cyclically Adjusted PS Ratio of today is 7.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Procter & Gamble Health was 11.33. The lowest was 5.58. And the median was 6.98.


Procter & Gamble Health  (BOM:500126) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Procter & Gamble Health's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5760.50/790.61
=7.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Procter & Gamble Health was 11.33. The lowest was 5.58. And the median was 6.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Procter & Gamble Health Cyclically Adjusted Revenue per Share Related Terms


Procter & Gamble Health Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Procter & Gamble Health's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procter & Gamble Health Cyclically Adjusted Revenue per Share Chart

Procter & Gamble Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 663.12 704.23 738.32 749.24 779.41

Procter & Gamble Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 759.59 767.66 772.69 779.41 790.61

BOM:500126 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procter & Gamble Health Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Procter & Gamble Health's Cyclically Adjusted PS Ratio falls into.


BOM:500126
76GF Score
Procter & Gamble Health Ltd BOM:500126
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procter & Gamble Health Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Procter & Gamble Health's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=219.102/167.3573*167.3573
=219.102

Current CPI (Jun. 2026) = 167.3573.

Procter & Gamble Health Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 162.171 105.961 256.136
201612 150.470 105.196 239.384
201703 137.887 105.196 219.366
201706 99.530 107.109 155.516
201709 124.019 109.021 190.380
201712 107.577 109.404 164.563
201803 119.348 109.786 181.933
201806 132.704 111.317 199.512
201809 136.258 115.142 198.049
201812 123.128 115.142 178.965
201903 139.158 118.202 197.028
201906 140.769 120.880 194.894
201909 135.627 123.175 184.276
201912 142.639 126.235 189.105
202003 137.413 124.705 184.412
202006 121.040 127.000 159.503
202009 159.028 130.118 204.541
202012 144.737 130.889 185.063
202103 132.026 131.771 167.682
202106 161.124 134.084 201.107
202109 164.555 135.847 202.724
202112 167.339 138.161 202.702
202203 161.240 138.822 194.384
202206 164.721 142.347 193.662
202209 179.021 144.661 207.108
202212 186.875 145.763 214.560
202303 193.559 146.865 220.567
202306 167.030 150.280 186.011
202309 183.693 151.492 202.931
202312 186.751 152.924 204.377
202403 151.831 153.035 166.041
202406 157.765 155.789 169.480
202409 188.813 157.882 200.144
202412 186.608 158.323 197.256
202503 187.366 157.552 199.027
202506 204.073 159.755 213.784
202509 196.481 162.289 202.617
202512 225.217 163.281 230.840
202603 223.176 164.272 227.367
202606 219.102 167.357 219.102

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹790.61 mean?
Procter & Gamble Health (BOM:500126) has a Cyclically Adjusted Revenue per Share of ₹790.61 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Procter & Gamble Health and its competitors.
Is Procter & Gamble Health's Cyclically Adjusted Revenue per Share too high?
Procter & Gamble Health's current Cyclically Adjusted Revenue per Share is ₹790.61. Overall, Procter & Gamble Health has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Cyclically Adjusted Revenue per Share compare to ZTS?
Procter & Gamble Health's Cyclically Adjusted Revenue per Share of ₹790.61 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Procter & Gamble Health and its competitors. Procter & Gamble Health's current Cyclically Adjusted Revenue per Share is ₹790.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,799.13, compared to a current price of ₹5,760.50 — trading 0.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹790.61. Procter & Gamble Health's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Cyclically Adjusted Revenue per Share is ₹790.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?

Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued. The current stock price of ₹5,760.50 is trading 0.7% below its estimated GF Value™ of ₹5,799.13. GuruFocus considers Procter & Gamble Health to be Fairly Valued.

Key valuation signals for BOM:500126:

  • Cyclically Adjusted Revenue per Share: ₹790.61
  • GF Value™: ₹5,799.13 vs. price of ₹5,760.50 (0.7% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Procter & Gamble Health Business Description

Other Exchanges PGHL:India
Address Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
76GF Score

Get the complete analysis for BOM:500126

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,760.50
Price
₹5,799.13
GF Value